Vetoquinol SA
PAR:VETO
Net Margin
Vetoquinol SA
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| FR |
|
Vetoquinol SA
PAR:VETO
|
892.3m EUR |
9%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
683.1B USD |
24%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
357.9B USD |
16%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
193.7B CHF |
20%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
171.5B CHF |
23%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
155.3B GBP |
13%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
196.4B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
162.4B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
122.3B USD |
13%
|
Vetoquinol SA
Glance View
Vétoquinol SA operates as a global animal health company. The company is headquartered in Lure, Bourgogne-Franche-Comte. The company went IPO on 2006-11-16. The Company’s product portfolio is divided between livestock, such as cattle and pigs, and companion animals, including dogs and cats. Vetoquinol SA’s offering includes anti-infectives, such as Marbocyl; anti- pain inflammatories, which comprise Tolfedine, intended for dogs and cats, and Tolfine for livestock, and cardiovascular and nephrology treatment, such as Prilium, an oral daily administration formula for dogs, among others. The firm markets over 700 products, in such countries as France, Austria, Canada, Italy, Poland, Spain and the Netherlands, among others. The company trades its products throughout Europe, North America, Africa, the Middle East and Pacific Asia. In April 2014, it acquired Bioniche's animal health business.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Vetoquinol SA's most recent financial statements, the company has Net Margin of 8.8%.
You don't have any saved screeners yet